XCUR - Exicure Corp PEG Multiple

Brandmark of Exicure Corp (XCUR)

The risks of targeted implementation of laboratory robots and screening automation are evident through the weighted P/E relative to earnings growth rates, where 0.00 captures the magnitude of this parameter. Bioethical standards and data protection, as well as center energy efficiency and the filtration of harmful emissions to minimize environmental damage, ensure the stability of Exicure, Inc. (XCUR).

XCUR: Exicure, Inc. PEG Multiple 07/04/2022 - 11/11/2026
Finished products of Exicure Inc.

The PEG ratio compares the current P/E multiple with earnings growth rates, revealing an imbalance between price and development dynamics. The PEG analytical indicator visualizes this proportion, where values below one signal a fundamental undervaluation of the asset. This metric measures the cost efficiency of each unit of future growth. For Exicure, Inc. (XCUR), this reflects market expectations for the SNA platform. Successful clinical trials and alliances with pharma behemoths could radically alter the trajectory of this indicator.

Competing companies

Price/Earnings to Growth Multiple Tempus AI, Inc TEM|Qiagen Group - Price/Earnings to Growth Multiple|PEG Multiple Isis Pharmaceuticals IONS|RGEN - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio RNA (aviditybiosciences.com)|CRSP: PEG Multiple|Price to Earnings Adjusted for Growth Rate GeneDx Holdings (WGS)|Price/Earnings to Growth Multiple RARE|BEAM: Growth-Adjusted Payback Ratio|PEG Multiple SRPT|Growth-Adjusted Market Cap to Net Income twistbioscience.com|Price/Earnings to Growth Ratio 10x Genomics TXG|NTLA: Growth-Adjusted P/E Ratio|Stoke - PEG Multiple|BioLife (BLFS) - Price/Earnings to Growth Multiple|WVE (Wave Life Sciences) - Price/Earnings to Growth Multiple|MAZE - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple SION|Growth-Adjusted P/E Ratio PRME (Prime Medicine Inc)|PEG Multiple TSHA|Price/Earnings to Growth Multiple uniQure Pharma QURE|MeiraGTx Holdings plc - Price/Earnings to Growth Multiple|PEG Multiple regenxbio.com RGNX|SLDB - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio OCGN (Ocugen Inc)|PACB: PEG Multiple|Growth-Adjusted P/E Ratio BNTC|Price/Earnings to Growth Ratio Design Therapeutics|Growth-Adjusted P/E Ratio RCKT (rocketpharma.com)|PEG Multiple FDMT|PEG Multiple lexeotx.com (LXEO)|PEG Multiple KRRO (Korro Bio)|Editas Corp (EDIT) - Price to Earnings Adjusted for Growth Rate|SLN: Price/Earnings to Growth Multiple|PRQR (ProQR Therapeutics N.V.) - Growth-Adjusted P/E Ratio|CDXS: PEG Multiple|SGMO - Growth-Adjusted Market Cap to Net Income|NAUT (Nautilus Biotechnology, Inc.) - PEG Multiple|Price/Earnings to Growth Multiple Metagenomi Therapeutics (MGX)|Price/Earnings to Growth Multiple DTIL (Precision BioSciences)|PEG Multiple generationbio.com (GBIO)|Price/Earnings to Growth Ratio Boundless Bio BOLD|Growth-Adjusted Payback Ratio IMNN|RXi Pharmaceuticals - PEG Multiple|Price to Earnings Adjusted for Growth Rate Mustang Bio, Inc.|RNAZ (transcodetherapeutics.com) - Price/Earnings to Growth Multiple|Bionano Genomics - Growth-Adjusted Payback Ratio|APDN (Applied DNA Sciences, Inc.) - PEG Multiple|bluebird bio Inc. (BLUE) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|Omega Therapeutics Corp - Growth-Adjusted P/E Ratio|PEG Multiple OMIC (Singular Genomics Systems)|RGLS - Price/Earnings to Growth Multiple|SYRS: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Telesis Bio Inc. TBIO|TCON (TRACON) - Price/Earnings to Growth Multiple|Growth-Adjusted P/E Ratio UBX